Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Takeda, PeptiDream to Develop Peptide Drug Conjugates for Neuromuscular Diseases
December 23, 2020
- Nichi-Iko Stops Supply of Clinoril Due to Dissolution Issue
December 23, 2020
- Meiji, Again, Halts Supply of Kobayashi Kako-Made Drugs after On-Site Inspections
December 23, 2020
- Sosei, GSK Seal Global Deal Targeting GI Disorders
December 22, 2020
- Xospata Fails to Hit Goal in PIII Combo Trial: Astellas
December 22, 2020
- FDA Approves Iclusig for Resistant/Intolerant CML
December 22, 2020
- Takeda Offloads 5 Non-Core Assets in China for US$322 Million
December 22, 2020
- Takeda Slated to Launch Japan PI/II for Moderna Shot in January
December 22, 2020
- Mirogabalin Hits Primary Endpoint in PIII for Central Neuropathic Pain After Spinal Cord Injury: Daiichi Sankyo
December 21, 2020
- Eisai's New Manufacturing Site Completed, Set to Begin Lenvima Production in FY2021
December 21, 2020
- Teijin Hooks Up with Chinese Firm on Small Molecule R&D
December 21, 2020
- Decision on Pfizer Vaccine Unlikely to Come before Japan Data Submission Slated by February
December 21, 2020
- Sanofi Files Sarclisa for Add'l Usage/Dosage in Japan
December 21, 2020
- Edirol Approved in China: Chugai
December 21, 2020
- Pfizer/BioNTech’s COVID-19 Vaccine Filed in Japan, Exceptional OK Eyed
December 18, 2020
- 5%-Plus Discrepancy Threshold for Off-Year Re-Pricing Draws Fire from Pharma, Wholesalers
December 18, 2020
- 2nd Death Reported for Tainted Itraconazole User, Doctor Says Causal Link Unlikely
December 18, 2020
- Otsuka Gets Japan, European Rights to Aurinia’s Lupus Nephritis Drug
December 18, 2020
- More Drug Makers Launching “Follow-on AGs”; Norvasc, Metgluco AGs Listed in December
December 18, 2020
- Gilead Japan Chief Disappointed by WHO’s Recommendation Against Veklury; Label Expansion Eyed for Moderately Ill Patients
December 18, 2020
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…